DuoGlide MonLisa Touch - Technologie laser hybride (CO2 et 1540nm)
DUOGlide assure une flexibilité maximale
plus efficace avec des temps de guérison plus courts.
Le choix des systèmes de scannage
µ-Scan V2LR (MonaLisa Touch Scanner)
Colposcan
D-PULSE - La forme spécifique de l’impulsion pour la muqueuse vaginale
D-Pulse est constituée de deux parties
- Une première partie de grande puissance de pointe et constante qui permet l'élimination superficielle rapide et indolore de la muqueuse épithéliale atrophiée
- Une deuxième partie variable de plus faible puissance de pointe et des temps d'émission plus longs, offrant ainsi la possibilité à l'énergie laser de pénétrer dans la muqueuse et de bien la stimuler en profondeur.
Le DuoGlide est unique en son genre !
Savoir-faire dans le domaine du laser CO2 et expérience avec MonaLisa Touch®
La synergie gagnante de deux longueurs d`onde
Contrôle total et efficacité maximale
Multidisciplinarité et flexibilité
Parfaite adéquation entre temps d`arrêt et résultats
Fiabilité maximale
Fonction SmartStack
La fonction SmartStack permet d`émettre 1 à 5 impulsions successives au même endroit (DOT).
La fonction SmartStack fait du Glide/DUOGlide l`un des systèmes les plus sûrs et les plus efficaces du marché.
Un maximum d`avantages
- Parfait contrôle de l`effet thermique : entre les impulsions, les tissus se refroidissent, ce qui réduit les dommages thermiques et le risque d`effets secondaires indésirables
- Contrôle précis de la profondeur d`évaporation : prévient les saignements abondants, ce qui accélère la récupération et offre un meilleur confort au patient.
Deka Mela s.r.l.
Caractéristiques techniques
|
LASER CO2 |
. |
|
Type de laser |
CO2 RF - PSD® |
|
Longueur d'onde |
10.6 μm |
|
Mode d'émission laser |
TEM00 |
|
Types d'émissions |
CW - SP - DP - HP - UP |
|
Puissance CW (onde continue) |
0.1 - 60 W max |
|
IR LASER |
. |
|
Longueur d'onde |
1540 nm |
|
Power |
From 2 W to 10 W |
|
DONNEES GENERALES |
. |
|
Interne Base de données interne |
Plus de 100 protocoles enregistrés en usine, possibilité de mise à niveau via USB. Possibilité pour l'utilisateur de définir et d'enregistrer un nombre illimité de protocoles |
|
Interface utilisateur |
Color LCD Touch Screen |
|
Dimensions et poids |
137 (hauteur) x 42 (longueur) x 54 (profondeur) cm - 70 kg |
Liens
Fabricant : DEKA
DuoGlide Le laser CO2 le plus moderne pour le photorajeunissement
DUOGlide dispose en option d`un micro-scanner pour les traitements en médecine esthétique et en chirurgie dermatologique
Lien vers Derma
Studien zu MonaLisa Touch und Lichen sclerosus
V2LR_Baggish_J Gyn Surg_Dec_2016.eng.IN PRESS (https://www.liebertpub.com/doi/abs/10.1089/gyn.2016.0099) In the lichen sclerosus cohort 24/27 patients who had laser treatment reported cessation of itching and pain/discomfort; and 26/27 women demonstrated visible improvement of skin color, elasticity, vascularity following 3-4 laser treatments.
V2LR_Pagano_et_al_Menopause_2020.eng. (https://pubmed.ncbi.nlm.nih.gov/31934950/) vulvar lichen sclerosus resistant to long-term use of topic corticosteroid. We found a significant improvement in vulvar itching (χ [2] = 31,182, P < 0.001), vulvar dryness (χ [2] = 40,364, P < 0.001), superficial dyspareunia (χ [2] = 37,488, P < 0.001), and sensitivity during intercourse (χ [2] = 22,143, P < 0.001) after two CO2 laser cycles.
V2LR_Balchander_et_al_JLGTD_2020.eng (https://pubmed.ncbi.nlm.nih.gov/32068618/ ) Recalcitrant Lichen Sclerosus.
V2LR_Gardner_et_al_Menopause_2021.eng (https://pubmed.ncbi.nlm.nih.gov/33399322/) After the appropriate laser sessions, 72.5% of women described their improvement as significant or more than 66% improvement. In addition, there was a statistically significant reduction in vaginal pain, itching, dyspareunia, and dysuria.
V2LR_Burkett_et_al_O&G_2021.eng (https://pubmed.ncbi.nlm.nih.gov/33957642/ ) Randomized Controlled Trial. Clobetasol vs CO2 laser. Conclusion: Fractionated CO2 laser treatment showed significant improvement in subjective symptoms and objective measures compared with clobetasol propionate, without serious safety or adverse events at 6 months.
V2LR_Filippini_et_al_PPLS_2021.eng (https://pubmed.ncbi.nlm.nih.gov/34878932/ ) Results: VLS-related symptoms and other relevant parameters showed a statistically significant improvement (p < 0.001) after the first laser treatment and kept improving after second and third sessions. […] Vaginal dryness, itching, and burning were significantly improved as well. Most patients declared to be very satisfied with the results of the treatment. A total of 62.8% of the women expressed a satisfaction score ≥8 on a scale from 0 to 10. Conclusions: Fractional microablative CO2 laser treatment seems to be safe and effective to treat VLS and improve VLS-related symptoms.
Studien zu MonaLisa Touch und Stressinkontinenz (randomized trials)
V2LR_Cruz_et_al_Menopause_2017.eng IN PRESS (https://pubmed.ncbi.nlm.nih.gov/28763401/) Vaginal atrophy in donne in menopausa. E’ il primo studio in doppio cieco su MLT. E’ uno studio brasiliano del 2018. Valuta 3 gruppi: laser, estriol e laser + estriol
V2LR_Politano_et_al_Menopause_2019.eng (https://pubmed.ncbi.nlm.nih.gov/31246661/ ) GSM. Lo studio valuta 3 gruppi: laser versus promestriene and lubricant
V2LR_Paraiso_et_al_Menopause_Sep2019.eng (https://pubmed.ncbi.nlm.nih.gov/31574047/ ) GSM. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy. Conclusions: At 6 months, fractionated CO2 vaginal laser and vaginal estrogen treatment resulted in similar improvement in genitourinary syndrome of menopause symptoms as well as urinary and sexual function. Overall, 70% to 80% of participants were satisfied or very satisfied with either treatment and there were no serious adverse events.
V2LR_Ruanphoo_et_al_Menopause_2020.eng (https://pubmed.ncbi.nlm.nih.gov/32345787/ ) Vaginal atrophy. A randomized double-blinded sham-controlled trial.
V2LR_Aguiar_et_al_LSM_2020.eng (https://pubmed.ncbi.nlm.nih.gov/31990089/ ) Urinary Symptoms in Postmenopausal Women. A Randomized Clinical Trial. Evaluatio of Laser, Promestriene, and Vaginal Lubricant.
V2LR_Eftekar_et_al_JLMS_2020.eng (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369558/ ) Sexual Function in Menopausal Women. A Randomized Controlled Trial. CO2 Fractional Laser vs Premarin Vaginal Cream.
V2LR_Salvatore_et_al_Climacteric_2020.eng (https://pubmed.ncbi.nlm.nih.gov/33089713/ ) GSM. A randomized sham-controlled trial.
V2LR_Dutra_et_al_Menopause_2021.eng (https://pubmed.ncbi.nlm.nih.gov/34010934/ ) GSM. Laser vs vaginal estrogen. A randomized controlled trial. Results: Histological analysis showed a significant increase in the vaginal epithelium thickness at the end of treatment in females in both the laser therapy (P < 0.001) and topical estrogen therapy (P = 0.001) groups. […] Sexual function increased significantly over time in both the topical estrogen therapy (P < 0.001) and laser therapy (P < 0.001) groups. Subjective evaluation through physical examination showed a significant improvement in atrophy in both the groups.
Studien zu MonaLisa Touch und vulvovaginale Therapie (cancer survivors)
V2LR_Pieralli_et_al_Arch Gynecol Obstet_2016.eng https://pubmed.ncbi.nlm.nih.gov/27170261/ Vulvovaginal atrophy in breast cancer survivors
V2LR_Pagano_et_al_Menopause_2016.eng. https://pubmed.ncbi.nlm.nih.gov/27648595/ Vulvovaginal atrophy in breast cancer survivors
V2LR_Pieralli_et_al_ArchGynecolObstet_2017.eng https://pubmed.ncbi.nlm.nih.gov/28866727/ Vulvovaginal atrophy in breast cancer survivors
V2LR_Pagano_et_al_Menopause_2017.eng https://pubmed.ncbi.nlm.nih.gov/29286986/ Vulvovaginal atrophy in breast cancer survivors
V2LR_Gittens_et_al_JCLT_2018.eng https://pubmed.ncbi.nlm.nih.gov/29883233/ sexual function (also but not only in breast cancer patients)
V2LR_Becorpi_et_al_LasersMedSci_2018.eng https://pubmed.ncbi.nlm.nih.gov/29492713/ GSM cancer survivors
V2LR_Athanasiou_et_al_LMS_Aug2019.eng https://pubmed.ncbi.nlm.nih.gov/31396795/ Sexual health in cancer survivors
V2LR_Quick_et_al_SupportCareCancer_2019.eng https://pubmed.ncbi.nlm.nih.gov/31811486/ GSM in breast cancer survivors
V2LR_Angioli_et_al_IJGC_2020.eng https://pubmed.ncbi.nlm.nih.gov/32221022/ urogenital syndrome previous gynecological neoplasia. (Cancer survivors)
V2LR_Quick_et_al_Menopause_2021.eng https://pubmed.ncbi.nlm.nih.gov/33534429/ GSM in breast cancer survivors (sexual function)
V2LR_Gardner_et_al_Menopause_2021.eng https://pubmed.ncbi.nlm.nih.gov/33399322/ Vulvovaginal symptoms (in menopause, breast cancer, and lichen sclerosus)
V2LR_Siliquini_et_al_The_Breast_J_2021.eng https://pubmed.ncbi.nlm.nih.gov/33728801/ GSM in cancer patients
V2LR_Quick_et_al_JCM_2022.eng https://pubmed.ncbi.nlm.nih.gov/35160226/ GSM cancer survivors
V2LR_D`Oria_et_al_EJOGRB_2022.eng https://pubmed.ncbi.nlm.nih.gov/36037664/ vulvo-vaginal atrophy in cancer patients
Studien zu MonaLisa Touch und vulväre Schmerzen
V2LR_Goldstain_et_al_JSM_2023.eng https://pubmed.ncbi.nlm.nih.gov/36779572/ Vestibular pain. Safety and efficacy of fractional CO2 laser. A randomized, double-blind, sham-controlled, prospective clinical study. Multi-centres study getting very good results.
V2LR_Murina_et_al_GynecolEndocrinol_Oct2019.eng https://pubmed.ncbi.nlm.nih.gov/31637943/ Ospemifene + fractional CO2 laser for postmenopausal vulvar pain.
V2LR_Murina_et_al_J Sex Med_2016.eng https://pubmed.ncbi.nlm.nih.gov/27864031/ Fractional CO2 Laser Treatment for Vestibulodynia and GSM.
Studien zu DUOGlide MonaLisa Touch mit zwei Wellenlängen
DG_1540_Magni_et_al_Frontiers_2022.eng https://www.frontiersin.org/articles/10.3389/fmed.2022.1010878/full
It is a study on dermal fibroblasts but it is equally significant for understanding the principle of action of the second wavelength present in Monalisa Glide. Basically it is shown that not only the irradiation of fibroblasts with 1540 is not cytotoxic (i.e. it does not damage them) but on the contrary it stimulates their proliferation. This research aimed to evaluate the photobiomodulation effect of the 1540 nm wavelength treatment on the proliferation of cultured fibroblast and their ability to express type I and III collagen.
